Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy

• Published in: ACS nano Vol. 18; no. 9; pp. 7136 - 7147
• Main Authors: Zhang, Xuanbo, Wang, Kaiyuan, Zhao, Zhiqiang, Shan, Xinzhu, Wang, Yuequan, Feng, Zunyong, Li, Bingyu, Luo, Cong, Chen, Xiaoyuan, Sun, Jin
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 05.03.2024
• Subjects: Adjuvants, Immunologic; Animals; Cancer Vaccines; Immunotherapy; Mice; Nanoparticles; Nanovaccines; Neoplasms - therapy; nanovaccines; mRNA; guanidinium; cancer immunotherapy; adjuvants
• ISSN: 1936-0851; 1936-086X; 1936-086X
• DOI: 10.1021/acsnano.3c11637

Tapping into the innate immune system’s power, nanovaccines can induce tumor-specific immune responses, which is a promising strategy in cancer immunotherapy. However, traditional vaccine design, requiring simultaneous loading of antigens and adjuvants, is complex and poses challenges for mass production. Here, we developed a tumor nanovaccine platform that integrates adjuvant functions into the delivery vehicle, using branched polyguanidine (PolyGu) nanovaccines. These nanovaccines were produced by modifying polyethylenimine (PEI) with various guanidine groups, transforming PEI’s cytotoxicity into innate immune activation. The PolyGu nanovaccines based on poly­(phenyl biguanidine ) (Poly-PBG) effectively stimulated dendritic cells, promoted their maturation via the TLR4 and NLRP3 pathways, and displayed robust in vivo immune activity. They significantly inhibited tumor growth and extended mouse survival. The PolyGu also showed promise for constructing more potent mRNA-based nanovaccines, offering a platform for personalized cancer vaccine. This work advances cancer immunotherapy toward potential clinical application by introducing a paradigm for developing self-adjuvanting nanovaccines.